Ministry of Health Inspectors Investigate Use of Drug that Blocks Puberty in Children
Inspectors from the Ministry of Health have launched a review at the Careggi hospital in Florence to verify the use of a drug that blocks puberty in children. This move comes after questions were raised about the treatment of gender dysphoria in children and the use of the drug triptorelin, which has sparked debates about its implications and potential side effects.
Gender incongruence, a subtle and complex issue that affects children, has sparked the use of drugs like triptorelin to help control puberty and evaluate the transition process. The issue is highly complex and delicate, as there are no clear answers in the scientific community about the effects and reversibility of the drug.
The Ministry of Health has initiated this review to gain a better understanding of the paths relating to the treatment of gender dysphoria in children and the use of triptorelin. The group includes representatives of the Higher Institute of Health, the National Bioethics Committee, the Health commission and the direction of the ministry. This mission has been described as having “no punitive intent, but rather knowledge in the field of the paths implemented”.
The Tuscany Region has responded to the inspection, emphasizing the need for discussion and transparency in addressing these complex issues. It was noted that the Careggi Hospital Center is recognized at the national and European level as an excellence in this field and that the protocols for treatment are carried out in accordance with current legislation, national and international scientific recommendations, and the AIFA determination.
The inclusion of triptorelin in the list of medicines that can be dispensed entirely at the expense of the National Health Service is based on specific criteria to allow its use. These criteria include a confirmed diagnosis of gender dysphoria by a multidisciplinary and specialist team, as well as the lack of effectiveness of psychological, psychotherapeutic, and psychiatric assistance.
The debate surrounding the use of drugs like triptorelin and the treatment of gender dysphoria in children remains contentious due to the uncertain origins of gender incongruence. It is a multifaceted issue that involves a combination of biological, psychological, social, environmental, and cultural factors.
The review at the Careggi hospital and the ongoing discussions about the use of triptorelin highlight the need for more research and understanding of gender incongruence and the best approaches to treatment. The situation calls for sensitivity and a thoughtful approach to address the distress and discomfort that children with gender dysphoria face. As discussions continue, it is important to consider the well-being of these children and the complexities of their experiences.